IBIO iBio Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: IBIO

Price (delayed)

$1.43

Market cap

$71.04M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.57

Enterprise value

$25.51M

?
Relative Growth: Rel. Growth: 7
Relative Strength: Rel. Strength: 58
Relative Valuation: Rel. Valuation: 1
Relative Profitability: Rel. Profitability: 26

iBio is a global leader in plant-based biologics manufacturing. Its FastPharming® System combines vertical farming, automated hydroponics, and novel glycosylation technologies to rapidly deliver high-quality monoclonal antibodies, vaccines, bioinks and ...

Highlights
IBIO's debt is down by 46% YoY and by 5% from the previous quarter
The company's equity rose by 37% QoQ
The EPS has plunged by 84% YoY but it has grown by 43% from the previous quarter
The company's net income fell by 32% YoY and by 12% QoQ
iBio's gross profit has decreased by 20% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.ibioinc.com
Peers: EBS JNJ NKTR

Key stats

What are the main financial stats of IBIO

IBIO stock price

How has the iBio stock price performed over time
Intraday
2.14%
1 week
3.62%
1 month
-11.73%
1 year
93.35%
YTD
-25.91%
QTD
-18.29%

Financial performance

How have iBio's revenue and profit performed over time
Revenue
$300,000
Gross profit
$300,000
Operating income
-$28.96M
Net income
-$27.61M
Gross margin
100%
Net margin
-9,202%
The company's operating margin has shrunk by 115% YoY and by 14% QoQ
The operating income has dropped by 72% year-on-year and by 14% since the previous quarter
IBIO's net margin has plunged by 64% YoY and by 12% from the previous quarter
The company's net income fell by 32% YoY and by 12% QoQ

Price vs fundamentals

How does IBIO's price correlate with its fundamentals

Growth

What is iBio's growth rate over time

Valuation

What is iBio stock price valuation
P/E
N/A
P/B
0.64
P/S
570.09
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
85.02
The EPS has plunged by 84% YoY but it has grown by 43% from the previous quarter
IBIO's price to book (P/B) is 42% lower than its 5-year quarterly average of 1.1 and 9% lower than its last 4 quarters average of 0.7
The company's equity rose by 37% QoQ
IBIO's price to sales (P/S) is 52% more than its last 4 quarters average of 375.8
iBio's revenue has decreased by 20% YoY

Efficiency

How efficient is iBio business performance
The ROS has plunged by 65% YoY and by 12% from the previous quarter
iBio's return on equity has surged by 59% YoY and by 24% QoQ
The ROIC has soared by 51% YoY and by 19% from the previous quarter
iBio's return on assets has increased by 48% YoY and by 20% QoQ

Dividends

What is IBIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IBIO.

Financial health

How did iBio financials performed over time
iBio's total assets has increased by 33% from the previous quarter
IBIO's current ratio is up by 31% since the previous quarter
IBIO's debt is 97% less than its equity
The company's debt to equity has shrunk by 92% YoY and by 25% QoQ
IBIO's debt is down by 46% YoY and by 5% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.